[go: up one dir, main page]

SG11201502887WA - Antibody-drug conjugate - Google Patents

Antibody-drug conjugate

Info

Publication number
SG11201502887WA
SG11201502887WA SG11201502887WA SG11201502887WA SG11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA SG 11201502887W A SG11201502887W A SG 11201502887WA
Authority
SG
Singapore
Prior art keywords
antibody
drug conjugate
conjugate
drug
Prior art date
Application number
SG11201502887WA
Inventor
Takeshi Masuda
Hiroyuki Naito
Takashi Nakada
Masao Yoshida
Shinji Ashida
Hideki Miyazaki
Yuji Kasuya
Koji Morita
Yuki Abe
Yusuke Ogitani
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50477169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201502887W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of SG11201502887WA publication Critical patent/SG11201502887WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201502887WA 2012-10-11 2013-10-10 Antibody-drug conjugate SG11201502887WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012225887 2012-10-11
PCT/JP2013/006069 WO2014057687A1 (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Publications (1)

Publication Number Publication Date
SG11201502887WA true SG11201502887WA (en) 2015-05-28

Family

ID=50477169

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201502887WA SG11201502887WA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate
SG10201804788XA SG10201804788XA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201804788XA SG10201804788XA (en) 2012-10-11 2013-10-10 Antibody-drug conjugate

Country Status (31)

Country Link
US (6) US10195288B2 (en)
EP (3) EP2907824B1 (en)
JP (9) JP5953378B2 (en)
KR (14) KR102540419B1 (en)
CN (4) CN109081871B (en)
AU (4) AU2013328111B2 (en)
BR (3) BR122021014396B1 (en)
CA (2) CA3021435C (en)
CY (2) CY1120363T1 (en)
DK (2) DK3342785T3 (en)
ES (2) ES2773710T3 (en)
HK (2) HK1210477A1 (en)
HR (2) HRP20180870T1 (en)
HU (2) HUE039000T2 (en)
IL (5) IL294622B2 (en)
LT (2) LT2907824T (en)
MX (3) MX364484B (en)
MY (1) MY170251A (en)
NZ (4) NZ705394A (en)
PH (2) PH12015500667B1 (en)
PL (2) PL2907824T3 (en)
PT (2) PT3342785T (en)
RS (2) RS57278B1 (en)
RU (1) RU2664465C2 (en)
SG (2) SG11201502887WA (en)
SI (2) SI3342785T1 (en)
SM (2) SMT201800344T1 (en)
TR (1) TR201809636T4 (en)
TW (9) TWI650312B (en)
WO (1) WO2014057687A1 (en)
ZA (2) ZA201501825B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963870A (en) * 2016-06-08 2019-07-02 艾伯维公司 Anti-B7-H3 Antibodies and Antibody Drug Conjugates
WO2021190602A1 (en) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Preparation method for antibody medicament conjugate

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122021014396B1 (en) * 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited INTERMEDIATE DRUG BINDING COMPOUNDS, AND BINDING
JP6272230B2 (en) 2012-10-19 2018-01-31 第一三共株式会社 Antibody-drug conjugate conjugated with a linker containing a hydrophilic structure
CN111228510B (en) 2013-12-25 2024-06-18 第一三共株式会社 Anti-TROP2 Antibody-Drug Conjugate
PL3466976T3 (en) * 2014-01-31 2021-12-20 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
JP2017114763A (en) * 2014-03-26 2017-06-29 第一三共株式会社 Anti-CD98 antibody-drug conjugate
WO2015155976A1 (en) * 2014-04-10 2015-10-15 第一三共株式会社 (anti-her2 antibody)-drug conjugate
CN106163559B (en) * 2014-04-10 2020-02-18 第一三共株式会社 Anti-HER3 Antibody-Drug Conjugates
IL290959B2 (en) * 2015-06-29 2023-04-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate compisitions and methods for producing same
WO2017110923A1 (en) * 2015-12-24 2017-06-29 旭硝子株式会社 Resin composition, substrate, and cell culture method
MX394519B (en) * 2016-04-15 2025-03-24 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
EP3468993A1 (en) * 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN107840892A (en) * 2016-09-20 2018-03-27 上海药明生物技术有限公司 Novel Anti-PCSK9 Antibody
JPWO2018110515A1 (en) 2016-12-12 2019-10-24 第一三共株式会社 Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018135501A1 (en) * 2017-01-17 2018-07-26 第一三共株式会社 Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
US20200061031A1 (en) 2017-02-28 2020-02-27 Kinki University Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
TWI794230B (en) 2017-05-15 2023-03-01 日商第一三共股份有限公司 Anti cdh6 antibodies and anti cdh6 antibody drug conjugates, as well as manufacturing method thereof
CN109963591B (en) * 2017-08-04 2023-04-04 江苏恒瑞医药股份有限公司 B7H3 antibody-drug conjugate and medical application thereof
CN109106951A (en) * 2017-08-18 2019-01-01 四川百利药业有限责任公司 A kind of camptothecine-antibody coupling matter
CN118767159A (en) * 2017-08-23 2024-10-15 第一三共株式会社 Antibody-drug conjugate preparation and lyophilization thereof
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
AU2018327171B2 (en) 2017-08-31 2023-03-09 Daiichi Sankyo Company, Limited Improved method for producing antibody-drug conjugate
IL273471B2 (en) 2017-09-29 2023-09-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
CN111542324B (en) * 2018-02-11 2023-09-12 四川科伦博泰生物医药股份有限公司 Cytotoxic agent and conjugate thereof, preparation method and application thereof
ES2951674T3 (en) 2018-05-18 2023-10-24 Glycotope Gmbh Anti-MUC1 antibody
CN112638375A (en) 2018-06-15 2021-04-09 旗舰创业创新五公司 Increasing immune activity through modulation of post-cellular signaling factors
EP3828206A4 (en) 2018-07-25 2022-04-20 Daiichi Sankyo Company, Limited Effective method for manufacturing antibody-drug conjugate
WO2020022475A1 (en) 2018-07-27 2020-01-30 第一三共株式会社 Protein recognizing drug moiety of antibody-drug conjugate
TW202415410A (en) 2018-07-31 2024-04-16 日商第一三共股份有限公司 Use of antibody-drug conjugate
JP7458981B2 (en) 2018-08-06 2024-04-01 第一三共株式会社 Combination of antibody-drug conjugate and tubulin inhibitor
CN112739826A (en) 2018-08-23 2021-04-30 第一三共株式会社 Sensitivity markers for antibody-drug conjugates
CN112714649B (en) 2018-09-06 2024-07-02 第一三共株式会社 Cyclic dinucleotide derivatives and antibody drug conjugates thereof
US20220072144A1 (en) 2018-09-20 2022-03-10 Daiichi Sankyo Company, Limited Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
US20210353764A1 (en) * 2018-09-26 2021-11-18 Jiangsu Hengrui Medicine Co., Ltd. Ligand-drug conjugate of exatecan analogue, preparation method therefor and application thereof
KR20210068457A (en) * 2018-09-30 2021-06-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Anti-B7H3 antibody-exatecan analog conjugates and pharmaceutical uses thereof
KR20210091711A (en) 2018-11-14 2021-07-22 다이이찌 산쿄 가부시키가이샤 Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate
AU2019396895A1 (en) * 2018-12-11 2021-07-08 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate with PARP inhibitor
US20220040324A1 (en) * 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
DK3941946T3 (en) 2019-03-20 2025-03-24 Univ California CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
RS63715B1 (en) 2019-03-29 2022-11-30 Medimmune Ltd COMPOUNDS AND THEIR CONJUGATES
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
CN111689980A (en) * 2019-05-26 2020-09-22 四川百利药业有限责任公司 Camptothecin drug and antibody conjugate thereof
CN117731798A (en) * 2019-06-28 2024-03-22 泰州复旦张江药业有限公司 Antibody coupling drug, intermediate thereof, preparation method and application
WO2020259258A1 (en) * 2019-06-28 2020-12-30 上海复旦张江生物医药股份有限公司 Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof
CN114341162A (en) 2019-07-10 2022-04-12 赛博克萨2公司 Peptide conjugates of cytotoxins as therapeutic agents
WO2021007402A1 (en) 2019-07-10 2021-01-14 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021052402A1 (en) * 2019-09-18 2021-03-25 四川百利药业有限责任公司 Camptothecin derivative and conjugate thereof
EP4074345A4 (en) * 2019-12-12 2023-10-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-claudin antibody-drug conjugate and pharmaceutical use thereof
MX2022007312A (en) * 2019-12-16 2022-07-13 Jiangsu Hengrui Medicine Co Anti-cea antibody-exatecan analog conjugate and pharmaceutical use thereof.
JP2023509359A (en) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Combination anticancer therapy with inducers of iron-dependent cell degradation
MX2022009044A (en) 2020-01-22 2022-08-11 Shanghai Senhui Medicine Co Ltd ERIBULIN DERIVATIVE DRUG CONJUGATE, METHOD OF PREPARATION AND APPLICATION OF THE SAME IN MEDICINE.
JP2023510905A (en) 2020-01-22 2023-03-15 江蘇恒瑞医薬股▲ふん▼有限公司 ANTI-TROP-2 ANTIBODY-EXATECAN ANALOG CONJUGATE AND MEDICINAL USE THEREOF
AU2021226341A1 (en) 2020-02-25 2022-09-29 Mediboston Limited Camptothecin derivatives and conjugates thereof
BR112022015283A2 (en) 2020-03-06 2022-09-20 Daiichi Sankyo Co Ltd ANTIBODY-DRUG CONJUGATE INCLUDING CYCLIC DINUCLEOTIDE DERIVATIVES
CN115298220B (en) * 2020-03-24 2024-12-20 上海翰森生物医药科技有限公司 Antibody-drug conjugates and their medical uses
CA3175733A1 (en) 2020-03-25 2021-09-30 Shanghai Hengrui Pharmaceutical Co., Ltd. Pharmaceutical composition comprising antibody drug conjugate and use thereof
US20230140397A1 (en) * 2020-03-25 2023-05-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-psma antibody-exatecan analogue conjugate and medical use thereof
WO2021200131A1 (en) 2020-03-30 2021-10-07 国立研究開発法人国立がん研究センター Antibody drug conjugate
WO2021249228A1 (en) 2020-06-08 2021-12-16 四川百利药业有限责任公司 Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof
TW202216209A (en) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and atm inhibitor
CN116635082A (en) 2020-06-24 2023-08-22 阿斯利康(英国)有限公司 Combinations of antibody-drug conjugates and ATR inhibitors
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
TW202216207A (en) 2020-06-24 2022-05-01 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and cdk9 inhibitor
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
JP2023532339A (en) 2020-06-29 2023-07-27 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド Viruses engineered to promote sanotransmission and their use in treating cancer
US10997243B1 (en) 2020-06-30 2021-05-04 Snowflake Inc. Supporting unstructured, semi-structured, and structured files
US11361026B2 (en) 2020-06-30 2022-06-14 Snowflake Inc. Accessing files in a database stage using a user defined function
US11423081B1 (en) 2020-06-30 2022-08-23 Snowflake Inc. Accessing files in a database stage using a user defined function
JP2023532591A (en) 2020-07-06 2023-07-28 ビョンディス・ビー．ブイ． Antifolate linker-drug and antibody-drug conjugates
WO2022011075A1 (en) * 2020-07-10 2022-01-13 VelosBio Inc. Novel ror1 antibody immunoconjugates
IL309173A (en) * 2020-07-13 2024-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
WO2022014698A1 (en) 2020-07-17 2022-01-20 第一三共株式会社 Method for producing antibody-drug conjugate
AU2021323863A1 (en) * 2020-08-13 2023-03-23 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Antibody drug conjugate
JP2023537115A (en) 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム Methods of treating cancer using anti-CD73 antibodies
KR20230061360A (en) 2020-09-02 2023-05-08 다이이찌 산쿄 가부시키가이샤 Novel endo-β-N-acetylglucosaminidase
MX2023003778A (en) 2020-09-30 2023-04-26 Duality Biologics Suzhou Co Ltd Antitumor compound, and preparation method therefor and use thereof.
IL301921A (en) 2020-10-09 2023-06-01 Daiichi Sankyo Co Ltd Combining an antibody-drug conjugate and a selective 1PARP inhibitor
JP2023545581A (en) * 2020-10-12 2023-10-30 シーチュアン バイリ ファーム シーオー． エルティーディー Camptothecin derivatives and their ligand-drug complexes
WO2022078259A1 (en) * 2020-10-12 2022-04-21 四川百利药业有限责任公司 Deuterated camptothecin derivative and antibody-drug conjugate thereof
IL302812A (en) 2020-11-11 2023-07-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate combinations with anti-SIRP alpha antibody
TW202233249A (en) 2020-11-12 2022-09-01 日商第一三共股份有限公司 Treatment for mesothelioma comprising administering anti-b7-h3 antibody-drug conjugate
WO2022099762A1 (en) * 2020-11-12 2022-05-19 博瑞生物医药（苏州）股份有限公司 Antibody conjugate intermediate and preparation method therefor
EP4265274B1 (en) * 2020-12-18 2025-03-19 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
US20240050584A1 (en) * 2020-12-18 2024-02-15 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Trop2 targeting antibody-drug conjugate, and preparation method and use therefor
WO2022140504A1 (en) * 2020-12-23 2022-06-30 Shanghai Ruotuo Biosciences Co., Ltd. Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
AU2022208361A1 (en) * 2021-01-13 2023-07-27 Daiichi Sankyo Company, Limited Anti-dll3 antibody-drug conjugate
CN114805377A (en) * 2021-01-29 2022-07-29 明慧医药（杭州）有限公司 Toxin molecules suitable for antibody-drug conjugates
TW202241454A (en) 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
WO2022170971A1 (en) 2021-02-09 2022-08-18 苏州宜联生物医药有限公司 Bioactive substance conjugate, preparation method therefor and use thereof
KR20230157983A (en) 2021-03-12 2023-11-17 다이이찌 산쿄 가부시키가이샤 Method for manufacturing sugar chains and medicines containing sugar chains
WO2022194257A1 (en) * 2021-03-17 2022-09-22 江苏恒瑞医药股份有限公司 Preparation method for camptothecin derivative
IL305883A (en) 2021-03-18 2023-11-01 Seagen Inc Selective drug release from internalized conjugates of biologically active compounds
WO2022212784A1 (en) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2022217022A1 (en) 2021-04-10 2022-10-13 Profoundbio Us Co. Folr1 binding agents, conjugates thereof and methods of using the same
JP2024514174A (en) * 2021-04-14 2024-03-28 ジーンクアンタム ヘルスケア （スーチョウ） シーオー．， エルティーディー． Linkers, conjugates and their uses
EP4079327A1 (en) 2021-04-22 2022-10-26 Centaurus Polytherapeutics Payloads for drug-conjugates and their use for treating cancer
JP2024516631A (en) 2021-04-23 2024-04-16 プロファウンドバイオ ユーエス カンパニー Anti-CD70 antibodies, conjugates thereof and methods of using same
KR20240000532A (en) * 2021-04-26 2024-01-02 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Anti-nectin-4 antibodies and anti-nectin-4 antibody-drug conjugates, and medicinal uses thereof
CN113816969B (en) * 2021-04-30 2024-01-16 联宁（苏州）生物制药有限公司 Eptification control compound, antibody drug conjugate thereof and application thereof
US11645243B2 (en) 2021-06-07 2023-05-09 Snowflake Inc. Accessing files in a database stage using a user defined function
JP2024523422A (en) * 2021-06-17 2024-06-28 ミンフイ ファーマシューティカル （ハンチョウ） リミテッド Antitumor compounds and their applications
WO2023275025A1 (en) 2021-06-28 2023-01-05 Byondis B.V. Conjugates comprising phosphoantigens and their use in therapy
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202320857A (en) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 Linkers, drug linkers and conjugates thereof and methods of using the same
CN113402584A (en) * 2021-07-06 2021-09-17 联宁（苏州）生物制药有限公司 Synthetic method of intermediate LND1067-L1 of antibody-coupled drug linker
CN113527418B (en) * 2021-07-16 2022-05-03 成都普康唯新生物科技有限公司 A kind of preparation method of ADC linker
IL309884A (en) * 2021-07-19 2024-03-01 Zeno Man Inc Immunoconjugates and methods
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
CA3225598A1 (en) 2021-07-21 2023-01-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-trop2 antibody drug conjugate and its application
CA3231632A1 (en) 2021-09-15 2023-03-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer
EP4410830A1 (en) 2021-09-30 2024-08-07 Ajinomoto Co., Inc. Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
EP4420683A1 (en) 2021-10-18 2024-08-28 Daiichi Sankyo Company, Limited Anti-cd37 antibody-drug conjugate
CN117980327A (en) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 Specific coupling of antibodies
CN116120460A (en) 2021-11-15 2023-05-16 成都百利多特生物药业有限责任公司 Bispecific antibody-camptothecins drug conjugate and medical application thereof
US11814394B2 (en) * 2021-11-16 2023-11-14 Genequantum Healthcare (Suzhou) Co., Ltd. Exatecan derivatives, linker-payloads, and conjugates and thereof
TW202329936A (en) 2021-11-18 2023-08-01 英商阿斯特捷利康英國股份有限公司 Combination of antibody-drug conjugate and parp1 selective inhibitor
US20250090680A1 (en) 2021-11-19 2025-03-20 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
JPWO2023100829A1 (en) 2021-11-30 2023-06-08
MX2024006732A (en) 2021-12-03 2024-07-22 Systimmune Inc Anti-human trop2 antibody-camptothecin drug conjugate and medical use thereof.
US20250057968A1 (en) 2021-12-23 2025-02-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-dll3 antibody and pharmaceutical use thereof, and antibody-drug conjugate containing anti-dll3 antibody
CN116333135A (en) * 2021-12-24 2023-06-27 百奥泰生物制药股份有限公司 anti-FR alpha antibody, antibody drug conjugate and application thereof
JP2025503511A (en) 2021-12-28 2025-02-04 アストラゼネカ ユーケー リミテッド Combination of antibody-drug conjugate and RASG12C inhibitor
WO2023126823A1 (en) 2021-12-28 2023-07-06 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atr inhibitor
CN118613484A (en) 2021-12-30 2024-09-06 拜奥迪斯私人有限公司 Antifolate linker-drug and antibody-drug conjugates
WO2023138635A1 (en) * 2022-01-18 2023-07-27 甘李药业股份有限公司 Exatecan derivative-antibody conjugate and medical use thereof
JP2025503322A (en) 2022-01-25 2025-01-30 メディリンク セラピューティクス （スージョウ） カンパニー リミテッド Antibodies, conjugates and uses thereof directed against Her3
EP4477674A1 (en) 2022-02-09 2024-12-18 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
JPWO2023163234A1 (en) 2022-02-28 2023-08-31
EP4487873A1 (en) 2022-02-28 2025-01-08 UBE Corporation Antibody-drug conjugate
EP4488378A1 (en) 2022-03-02 2025-01-08 Daiichi Sankyo Company, Limited Method for producing fc-containing molecule
WO2023173026A1 (en) 2022-03-10 2023-09-14 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
IL315662A (en) 2022-03-16 2024-11-01 Astrazeneca Uk Ltd A characterization method for conjugating an anti-TROP 2 antibody and a drug for treatment
EP4494659A1 (en) 2022-03-18 2025-01-22 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
CN119095624A (en) 2022-04-27 2024-12-06 第一三共株式会社 Combinations of antibody-drug conjugates with EZH1 and/or EZH2 inhibitors
WO2023218378A1 (en) 2022-05-11 2023-11-16 Daiichi Sankyo Company, Limited Combination of an antibody specific for a tumor antigen and a cd47 inhibitor
KR20250012631A (en) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 Dosing of anti-CDH6 antibody-drug conjugates
WO2023234426A1 (en) 2022-06-03 2023-12-07 Ｕｂｅ株式会社 Antibody-multidrug conjugate
CN119677542A (en) 2022-06-03 2025-03-21 Ｕｂｅ株式会社 Antibody-multidrug conjugate precursors and synthetic intermediates thereof
IL317340A (en) 2022-06-07 2025-01-01 Duality Biologics Suzhou Co Ltd Anti-b7h3 antibody-drug conjugate and use thereof
EP4536666A1 (en) * 2022-06-09 2025-04-16 BeiGene, Ltd. Antibody drug conjugates
CN119365216A (en) 2022-06-15 2025-01-24 上海翰森生物医药科技有限公司 A pharmaceutical composition containing an antibody-drug conjugate and its use
CN115160403A (en) * 2022-07-05 2022-10-11 上海彩迩文生化科技有限公司 Specific topoisomerase inhibitor and conjugate used for antibody drug and preparation method thereof
CN118955615A (en) * 2022-07-05 2024-11-15 上海药明合联生物技术有限公司 Coupling Linker
WO2024014837A1 (en) 2022-07-11 2024-01-18 주식회사 피노바이오 Ddx5 protein-binding camptothecin derivatives and prodrugs thereof
WO2024012524A1 (en) 2022-07-14 2024-01-18 苏州宜联生物医药有限公司 Antibody-drug conjugate, and preparation method therefor and use thereof
CN119462943A (en) 2022-07-15 2025-02-18 启德医药科技（苏州）有限公司 Antibodies, linkers, loads, conjugates and their applications
WO2024020536A1 (en) * 2022-07-22 2024-01-25 Nj Bio, Inc. Hexacyclic topoisomerase inhibitors having cytotoxic activity on cancer cells
CN119546344A (en) 2022-07-27 2025-02-28 明慧医药（杭州）有限公司 Antibody drug conjugate and application thereof
CN119654169A (en) 2022-07-28 2025-03-18 阿斯利康(英国)有限公司 Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
CN117510515A (en) * 2022-07-28 2024-02-06 明慧医药（杭州）有限公司 Toxin molecules suitable for antibody-drug conjugates
TW202415409A (en) 2022-08-02 2024-04-16 中國商諾納生物（蘇州）有限公司 MSLN antibody-drug conjugate
WO2024041587A1 (en) 2022-08-25 2024-02-29 启德医药科技（苏州）有限公司 Pharmaceutical composition of antibody drug conjugate
IL319250A (en) 2022-08-29 2025-04-01 Daiichi Sankyo Company Ltd Antibody-drug conjugate including mutant fc region
US20240116945A1 (en) * 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024073436A2 (en) * 2022-09-26 2024-04-04 Solve Therapeutics, Inc. Compositions and uses thereof
WO2024067811A1 (en) * 2022-09-30 2024-04-04 Beigene, Ltd. Ligand-drug conjugate of exatecan analogue, and medical use thereof
US20240174732A1 (en) 2022-10-05 2024-05-30 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
AR130844A1 (en) 2022-10-25 2025-01-22 Merck Sharp & Dohme Llc EXATECAN-DERIVED ADC PAYLOAD LINKER, PHARMACEUTICAL COMPOSITIONS, AND THEIR USES
TW202434306A (en) 2022-11-24 2024-09-01 瑞士商百濟神州瑞士有限責任公司 Anti-cea antibody drug conjugates and methods of use
WO2024109949A1 (en) * 2022-11-25 2024-05-30 明慧医药（杭州）有限公司 Anti-tumor compound and use thereof
CN118105508A (en) * 2022-11-29 2024-05-31 四川科伦博泰生物医药股份有限公司 Medicinal linker compound, preparation method and application thereof
TW202440169A (en) 2022-11-30 2024-10-16 日商第一三共股份有限公司 Combination of antibody-drug conjugates and dnmt inhibitors
CN116621927B (en) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 Antibody coupling intermediate with irinotecan and C-lock fixed-point coupling group, coupling method and antibody coupling drug
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024165045A1 (en) 2023-02-09 2024-08-15 Beigene, Ltd. Self-stabilizing linker conjugates
WO2024179470A1 (en) * 2023-02-27 2024-09-06 苏州盛迪亚生物医药有限公司 Anti-dll3 antibody, and antibody-drug conjugate and pharmaceutical use thereof
CN118666946A (en) * 2023-03-15 2024-09-20 上海亲合力生物医药科技股份有限公司 Linker and conjugated drug using the same, antibody conjugated drug and application thereof
TW202438114A (en) * 2023-03-23 2024-10-01 瑞士商百濟神州瑞士有限責任公司 Bioactive conjugate, preparation method therefor and use thereof
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211234A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024211236A2 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
WO2024213091A1 (en) 2023-04-13 2024-10-17 Genequantum Healthcare (Suzhou) Co., Ltd. Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof
TW202448455A (en) * 2023-05-06 2024-12-16 大陸商上海齊魯製藥研究中心有限公司 A deuterated camphor alkaloid compound and its preparation and application
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof
CN119522111A (en) * 2023-05-16 2025-02-25 石药集团巨石生物制药有限公司 Pharmaceutical composition of antibody drug conjugate
CN119546347A (en) * 2023-06-29 2025-02-28 石药集团巨石生物制药有限公司 Antibody-drug conjugates and uses thereof
WO2025005240A1 (en) * 2023-06-30 2025-01-02 第一三共株式会社 Antibody-drug conjugate production method including purification step using activated carbon material
WO2025036480A1 (en) * 2023-08-16 2025-02-20 中山康方生物医药有限公司 Compound and antibody-drug conjugate comprising same
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5658920A (en) 1991-01-16 1997-08-19 Daiichi Pharmaceutical Co., Ltd. Substituted 1H,12H-benz-[DE]pyrano[3',4':6,7] indolizino[1,2-B]quinoline-10,13(9H,15H)-dione compound
JP3008226B2 (en) 1991-01-16 2000-02-14 第一製薬株式会社 Hexacyclic compounds
JPH0559061U (en) 1991-04-18 1993-08-03 株式会社ケイヴイシー Ball valve
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233782D1 (en) 1991-12-02 2010-05-20 Medical Res Council Preparation of Autoantibodies on Phage Surfaces Starting from Antibody Segment Libraries
JP3507073B2 (en) 1992-03-24 2004-03-15 ケンブリッジ アンティボディー テクノロジー リミティド Methods for producing members of a specific binding pair
JP3359955B2 (en) 1992-07-16 2002-12-24 第一製薬株式会社 Antitumor agent
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JPH0687746U (en) 1993-06-02 1994-12-22 株式会社ユニシアジェックス Hydraulic buffer reservoir tube structure
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
AU690171B2 (en) 1993-12-03 1998-04-23 Medical Research Council Recombinant binding proteins and peptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
JPH08337584A (en) 1995-04-10 1996-12-24 Dai Ichi Seiyaku Co Ltd Fused hexacyclic amino compound, pharmaceutical containing the same, and process for producing the same
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
JPH1095802A (en) 1995-12-28 1998-04-14 Tanabe Seiyaku Co Ltd Camptothecine derivative
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
JPH1171280A (en) 1997-06-26 1999-03-16 Tanabe Seiyaku Co Ltd Medicine composition
JPH1192405A (en) * 1997-09-19 1999-04-06 Dai Ichi Seiyaku Co Ltd Medicinal complex
ES2434961T5 (en) 1998-04-20 2018-01-18 Roche Glycart Ag Antibody glycosylation engineering to improve antibody-dependent cell cytotoxicity
US6835807B1 (en) * 1998-05-22 2004-12-28 Daiichi Pharmaceuticals Co., Ltd. Drug complex and drug delivery system
KR20010090602A (en) 1998-10-30 2001-10-18 스즈키 다다시 DDS Compounds and Method for Assaying the Same
EP1914244B1 (en) 1999-04-09 2013-05-29 Kyowa Hakko Kirin Co., Ltd. Method of modulating the activity of functional immune molecules
JP2002060351A (en) 2000-03-22 2002-02-26 Dai Ichi Seiyaku Co Ltd Dds compound comprising drug having hydroxy group
BR0112287A (en) * 2000-06-29 2003-05-06 Daiichi Seiyaku Co Dds compound and its preparation method
WO2002005855A1 (en) 2000-07-13 2002-01-24 Daiichi Pharmaceutical Co., Ltd. Pharmaceutical compositions containing dds compounds
CN1894406A (en) 2000-10-06 2007-01-10 协和发酵工业株式会社 Antibody composition-producing cell
US7090843B1 (en) 2000-11-28 2006-08-15 Seattle Genetics, Inc. Recombinant anti-CD30 antibodies and uses thereof
TWI313609B (en) 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor
RO123525B1 (en) 2001-11-01 2013-04-30 Uab Research Foundation Method for in-vitro selectively inducing apoptosis or inhibiting proliferation of target cells expressing dr5 and composition for selectively inducing apoptosis, which comprises a combination of antibodies
AU2002363939A1 (en) * 2001-11-20 2003-06-10 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
SI3483183T1 (en) 2002-03-01 2021-08-31 Immunomedics, Inc. Immunoconjugate comprising humanised rs7 antibodies
JP4959136B2 (en) 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド Immunoconjugates with cleavable linkages in cells
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
BRPI0508233A (en) 2004-02-26 2007-07-17 Inotek Pharmaceuticals Corp isoquinoline derivatives and methods for their use
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
MXPA06013413A (en) * 2004-05-19 2007-01-23 Medarex Inc Chemical linkers and conjugates thereof.
RU2404810C9 (en) 2004-06-01 2015-06-20 Дженентек, Инк. Conjugates antibody-medicinal agent and methods
AU2005316844A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
DE102005009099A1 (en) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh New camptothecin-peptide derivatives, useful for treating cancer
DE102005009084A1 (en) 2005-02-28 2006-08-31 Ktb Tumorforschungsgesellschaft Mbh New anthracyclin-peptide derivatives, useful for treating cancer, especially of the prostate, are cleaved, in the tumor, by prostate-specific antigen to release active antitumor agent and are transported by serum albumen
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
BRPI0711249A2 (en) 2006-05-30 2012-03-13 Genentech, Inc. ANTIBODIES, POLYNUCLEOTIDES, VECTORS, HOST CELLS, METHODS FOR MANUFACTURING AN ANTIBODY, TO DETECTION THE PRESENCE OF CD2 IN A BIOLOGICAL SAMPLE, TO TREAT A PROLIFERATIVE B-CELL DIFFERENCE, CELL FOR PROLIBA CULAR, CELL FOR CIBLES ANTI-BODY DRUG CONJUGATE. IMMUNOCONJUGATES, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, ANTIBODY-DRUG CONJUGATE, ANTIBODY-DRUG CONJUGATE COMPOUNDS, B-CELL DETECTION TEST AND MANUFACTURING ARTICLE
CN101490087B (en) * 2006-05-30 2013-11-06 健泰科生物技术公司 Antibodies and immunoconjugates and uses therefor
JPWO2007145306A1 (en) 2006-06-15 2009-11-12 国立大学法人 北海道大学 Retentive element in blood that is selectively degradable in tumor tissue
ITMI20061473A1 (en) 2006-07-26 2008-01-27 Indena Spa DERIVATIVES OF CAMPTOTECIN WITH ANTITUMORAL ACTIVITY
CA2673410A1 (en) 2006-12-21 2008-07-03 Schering Corporation Pyrrolo [3, 2-a] pyridine derivatives for inhibiting ksp kinesin activity
CN101687021B (en) * 2007-03-22 2013-04-17 斯隆-凯特琳癌症研究院 Uses of monoclonal antibody 8H9
HUE034763T2 (en) 2008-04-30 2018-02-28 Immunogen Inc Cross-linkers and their uses
EP2393512B1 (en) 2009-02-05 2016-10-26 ONCOXX Biotech s.r.l. Anti-trop-2 monoclonal antibodies and uses thereof in the treatment and diagnosis of tumors
EP3939617B1 (en) 2009-02-13 2024-11-13 Immunomedics, Inc. Intermediates for preparing conjugates with an intracellularly-cleavable linkage
JP5829520B2 (en) 2009-08-20 2015-12-09 国立大学法人 千葉大学 Colchicine derivatives
WO2011038159A2 (en) 2009-09-24 2011-03-31 Seattle Genetics, Inc. Dr5 ligand drug conjugates
KR20130062931A (en) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
CN105797168A (en) 2010-05-18 2016-07-27 天蓝制药公司 Compositions and method for treatment of autoimmune and other diseases
RU2012157167A (en) 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Polyfunctional antibody conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
CN104053672A (en) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2 specific antibody and use thereof
SG11201403085PA (en) 2011-12-14 2014-10-30 Seattle Genetics Inc Fgfr antibody drug conjugates (adcs) and the use thereof
US20130280282A1 (en) 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
KR20150023729A (en) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
US9517522B2 (en) * 2012-09-05 2016-12-13 Illinois Tool Works Inc. Self-aligning wire feeder assembly
BR122021014396B1 (en) 2012-10-11 2022-07-05 Daiichi Sankyo Company, Limited INTERMEDIATE DRUG BINDING COMPOUNDS, AND BINDING
JP6272230B2 (en) * 2012-10-19 2018-01-31 第一三共株式会社 Antibody-drug conjugate conjugated with a linker containing a hydrophilic structure
EP2927227A4 (en) 2013-01-03 2015-12-30 Celltrion Inc Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
CN103313390B (en) 2013-07-05 2016-01-20 江苏大学 A kind of WSN localization method based on double-movement beacon
PL3466976T3 (en) * 2014-01-31 2021-12-20 Daiichi Sankyo Company, Limited Anti-her2 antibody-drug conjugate
WO2015155976A1 (en) 2014-04-10 2015-10-15 第一三共株式会社 (anti-her2 antibody)-drug conjugate
US20190386950A1 (en) 2017-02-24 2019-12-19 Gil Hoon Chang Message sharing system and method for interactive application

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109963870A (en) * 2016-06-08 2019-07-02 艾伯维公司 Anti-B7-H3 Antibodies and Antibody Drug Conjugates
WO2021190602A1 (en) * 2020-03-25 2021-09-30 江苏恒瑞医药股份有限公司 Preparation method for antibody medicament conjugate

Also Published As

Publication number Publication date
US20250049782A1 (en) 2025-02-13
NZ746440A (en) 2019-11-29
TWI870275B (en) 2025-01-11
RU2018128384A (en) 2018-10-02
JP6952835B2 (en) 2021-10-27
IL294622B1 (en) 2023-06-01
CN113929738B (en) 2024-05-17
KR102584005B1 (en) 2023-09-27
KR20180030734A (en) 2018-03-23
CN113929738A (en) 2022-01-14
CY1122789T1 (en) 2021-05-05
PT3342785T (en) 2020-02-25
JP2022008581A (en) 2022-01-13
JP6371452B2 (en) 2018-08-08
KR20190135559A (en) 2019-12-06
CN104755494A (en) 2015-07-01
MX2019004502A (en) 2019-08-21
CA3021435C (en) 2021-10-12
AU2013328111A1 (en) 2015-03-12
US20200282073A1 (en) 2020-09-10
TW202448521A (en) 2024-12-16
TW202033499A (en) 2020-09-16
JP2020180124A (en) 2020-11-05
AU2013328111B2 (en) 2017-11-02
KR102456726B1 (en) 2022-10-20
RU2664465C2 (en) 2018-08-17
AU2018200308B2 (en) 2019-11-07
TW201811746A (en) 2018-04-01
TWI615152B (en) 2018-02-21
IL271760A (en) 2020-02-27
JP5953378B2 (en) 2016-07-20
EP2907824A4 (en) 2016-06-08
HK1256631A1 (en) 2019-09-27
AU2020200548B2 (en) 2022-08-25
NZ705394A (en) 2018-10-26
KR101901558B1 (en) 2018-09-21
CN104755494B (en) 2018-09-07
KR20230024433A (en) 2023-02-20
TW202448464A (en) 2024-12-16
LT2907824T (en) 2018-06-11
JP2018188455A (en) 2018-11-29
KR20210132240A (en) 2021-11-03
PH12015500667A1 (en) 2015-05-18
ES2671644T3 (en) 2018-06-07
EP3342785A1 (en) 2018-07-04
SG10201804788XA (en) 2018-07-30
CN115960111A (en) 2023-04-14
TWI870276B (en) 2025-01-11
KR102087017B1 (en) 2020-03-10
CA3021435A1 (en) 2014-04-17
US9808537B2 (en) 2017-11-07
IL294622A (en) 2022-09-01
KR102369419B1 (en) 2022-03-02
HUE048748T2 (en) 2020-08-28
RU2015113767A (en) 2016-12-10
US20190008981A1 (en) 2019-01-10
AU2022203560A1 (en) 2022-06-16
PT2907824T (en) 2018-06-07
SI3342785T1 (en) 2020-02-28
PL3342785T3 (en) 2020-09-07
IL238143B (en) 2020-01-30
ZA201501825B (en) 2022-05-25
KR101841818B1 (en) 2018-03-26
WO2014057687A1 (en) 2014-04-17
KR102237639B1 (en) 2021-04-07
MX364484B (en) 2019-04-29
PL2907824T3 (en) 2018-08-31
TW202444366A (en) 2024-11-16
TW201420117A (en) 2014-06-01
CA2885800A1 (en) 2014-04-17
JP2016196484A (en) 2016-11-24
AU2022203560B2 (en) 2025-02-06
SMT202000138T1 (en) 2020-05-08
IL238143A0 (en) 2015-05-31
TW202448463A (en) 2024-12-16
JP2023011799A (en) 2023-01-24
KR20210038728A (en) 2021-04-07
TW202448522A (en) 2024-12-16
IL294622B2 (en) 2023-10-01
HUE039000T2 (en) 2018-12-28
TW202444428A (en) 2024-11-16
TWI870274B (en) 2025-01-11
KR102540419B1 (en) 2023-06-05
BR122021014365B1 (en) 2022-07-05
CN109081871B (en) 2023-07-14
CA2885800C (en) 2018-12-04
TWI650312B (en) 2019-02-11
EP2907824B1 (en) 2018-04-11
SMT201800344T1 (en) 2018-09-13
TWI696611B (en) 2020-06-21
NZ740948A (en) 2019-11-29
JP6030267B1 (en) 2016-11-24
IL302494B2 (en) 2024-11-01
TW202444367A (en) 2024-11-16
US10195288B2 (en) 2019-02-05
DK3342785T3 (en) 2020-03-23
MX2015003903A (en) 2015-07-17
KR102052319B1 (en) 2019-12-05
TR201809636T4 (en) 2018-07-23
PH12018501433A1 (en) 2019-02-27
RS60000B1 (en) 2020-04-30
KR20220100727A (en) 2022-07-15
KR20200026323A (en) 2020-03-10
SI2907824T1 (en) 2018-06-29
JP6715888B2 (en) 2020-07-01
TW202444429A (en) 2024-11-16
EP3632471A1 (en) 2020-04-08
JP2017036274A (en) 2017-02-16
KR20220029776A (en) 2022-03-08
TWI870273B (en) 2025-01-11
KR102709509B1 (en) 2024-09-24
IL302494A (en) 2023-06-01
BR112015006521B1 (en) 2022-03-03
JP7170812B2 (en) 2022-11-14
US20240082413A1 (en) 2024-03-14
TW202448523A (en) 2024-12-16
KR20230142808A (en) 2023-10-11
KR20240144454A (en) 2024-10-02
ES2773710T3 (en) 2020-07-14
US20160279259A1 (en) 2016-09-29
KR20230086800A (en) 2023-06-15
NZ746439A (en) 2019-11-29
TW202448462A (en) 2024-12-16
IL271760B (en) 2022-08-01
JP7523506B2 (en) 2024-07-26
KR20220146669A (en) 2022-11-01
IL302494B1 (en) 2024-07-01
IL313147A (en) 2024-07-01
KR20180105271A (en) 2018-09-27
JPWO2014057687A1 (en) 2016-09-05
KR102320907B1 (en) 2021-11-02
LT3342785T (en) 2020-02-10
BR122021014396B1 (en) 2022-07-05
EP3342785B1 (en) 2019-12-25
JP6186045B2 (en) 2017-08-23
CN109081871A (en) 2018-12-25
JP2024147681A (en) 2024-10-16
KR102417310B1 (en) 2022-07-05
US12186310B2 (en) 2025-01-07
HRP20200353T1 (en) 2020-06-12
CY1120363T1 (en) 2019-07-10
HRP20180870T1 (en) 2018-07-13
US20150297748A1 (en) 2015-10-22
ZA201900820B (en) 2022-08-31
MX2020010964A (en) 2020-11-09
JP2018008982A (en) 2018-01-18
US11633493B2 (en) 2023-04-25
RU2018128384A3 (en) 2021-12-20
TWI757740B (en) 2022-03-11
US10973924B2 (en) 2021-04-13
RS57278B1 (en) 2018-08-31
AU2018200308A1 (en) 2018-02-01
PH12015500667B1 (en) 2019-03-06
MY170251A (en) 2019-07-13
DK2907824T3 (en) 2018-07-23
BR112015006521A2 (en) 2017-09-05
KR102498405B1 (en) 2023-02-09
HK1210477A1 (en) 2016-04-22
AU2020200548A1 (en) 2020-02-13
TW202233186A (en) 2022-09-01
KR20150067149A (en) 2015-06-17
EP2907824A1 (en) 2015-08-19
TW201920098A (en) 2019-06-01

Similar Documents

Publication Publication Date Title
ZA201900820B (en) Antibody-drug conjugate
HUS2300020I1 (en) Pyrrolobenzodiazepine-antibody conjugates
HRP20190056T1 (en) Anti-trop2 antibody-drug conjugate
ZA201502523B (en) Pyrrolobenzodiazepine-anitbody conjugates
SG10201605401WA (en) Antibody-drug conjugates
ZA201409119B (en) Polymer-nsaid conjugate
TWI879656B (en) Antibody-drug conjugate
TWI879657B (en) Antibody-drug conjugate
TWI879658B (en) Antibody-drug conjugate
TWI879659B (en) Antibody-drug conjugate